Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Respiratory Syncytial Virus Infections | 3 | 2018 | 1234 | 0.26 | Why? |
| Cytidine | 2 | 2020 | 219 | 0.22 | Why? |
| Ribonucleosides | 1 | 2020 | 95 | 0.20 | Why? |
| Cephalosporin Resistance | 1 | 2018 | 12 | 0.19 | Why? |
| Exoribonucleases | 2 | 2021 | 455 | 0.19 | Why? |
| Enteropathogenic Escherichia coli | 1 | 2018 | 11 | 0.19 | Why? |
| Middle East Respiratory Syndrome Coronavirus | 6 | 2020 | 8843 | 0.18 | Why? |
| Liraglutide | 1 | 2018 | 47 | 0.18 | Why? |
| Lactobacillus | 1 | 2018 | 92 | 0.17 | Why? |
| Glucagon-Like Peptide-1 Receptor | 1 | 2018 | 138 | 0.16 | Why? |
| Respiratory Syncytial Viruses | 2 | 2018 | 612 | 0.16 | Why? |
| Antibodies, Neutralizing | 7 | 2021 | 25288 | 0.14 | Why? |
| Respiratory Sounds | 1 | 2018 | 294 | 0.14 | Why? |
| Rhinovirus | 2 | 2017 | 979 | 0.14 | Why? |
| Escherichia coli Infections | 1 | 2018 | 348 | 0.14 | Why? |
| Enterobacteriaceae | 1 | 2018 | 395 | 0.14 | Why? |
| Th2 Cells | 1 | 2018 | 680 | 0.14 | Why? |
| Community-Acquired Infections | 2 | 2017 | 2328 | 0.13 | Why? |
| Gastroenteritis | 1 | 2018 | 489 | 0.13 | Why? |
| Enterobacteriaceae Infections | 1 | 2018 | 529 | 0.12 | Why? |
| Intestines | 1 | 2018 | 817 | 0.12 | Why? |
| beta-Lactamases | 1 | 2018 | 759 | 0.12 | Why? |
| Picornaviridae Infections | 1 | 2017 | 544 | 0.11 | Why? |
| Virus Replication | 3 | 2021 | 14331 | 0.10 | Why? |
| Murine hepatitis virus | 1 | 2019 | 1720 | 0.10 | Why? |
| Viral Vaccines | 3 | 2020 | 7560 | 0.10 | Why? |
| Viremia | 1 | 2017 | 1020 | 0.10 | Why? |
| Tennessee | 2 | 2021 | 243 | 0.10 | Why? |
| RNA, Messenger | 2 | 2020 | 5131 | 0.09 | Why? |
| Immunization, Secondary | 3 | 2021 | 1649 | 0.09 | Why? |
| Epitopes | 1 | 2019 | 4113 | 0.08 | Why? |
| Respiratory System | 2 | 2020 | 3213 | 0.08 | Why? |
| Spike Glycoprotein, Coronavirus | 5 | 2020 | 37182 | 0.08 | Why? |
| Carrier State | 1 | 2018 | 2100 | 0.08 | Why? |
| Diarrhea | 1 | 2018 | 2743 | 0.08 | Why? |
| Hospitalization | 4 | 2021 | 54280 | 0.08 | Why? |
| Quality Improvement | 1 | 2018 | 2435 | 0.07 | Why? |
| Schools | 1 | 2021 | 4187 | 0.07 | Why? |
| Hypoglycemic Agents | 1 | 2018 | 2165 | 0.07 | Why? |
| RNA Virus Infections | 1 | 2007 | 231 | 0.07 | Why? |
| Th1 Cells | 2 | 2020 | 1228 | 0.07 | Why? |
| Antibodies, Viral | 6 | 2021 | 51949 | 0.06 | Why? |
| Drug Resistance, Viral | 2 | 2020 | 1083 | 0.06 | Why? |
| Mice | 5 | 2020 | 21357 | 0.06 | Why? |
| Asymptomatic Infections | 1 | 2021 | 7218 | 0.06 | Why? |
| Viruses | 1 | 2015 | 2238 | 0.06 | Why? |
| Antiviral Agents | 5 | 2021 | 41703 | 0.05 | Why? |
| Vaccination | 3 | 2021 | 19050 | 0.05 | Why? |
| Infant | 6 | 2018 | 30274 | 0.05 | Why? |
| Crystallography, X-Ray | 2 | 2018 | 2689 | 0.05 | Why? |
| Child, Preschool | 6 | 2021 | 36283 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2018 | 4927 | 0.05 | Why? |
| RNA Viruses | 1 | 2007 | 824 | 0.05 | Why? |
| Adolescent | 9 | 2021 | 86841 | 0.05 | Why? |
| Hydroxylamines | 1 | 2020 | 182 | 0.05 | Why? |
| Respiratory Tract Diseases | 1 | 2007 | 1061 | 0.05 | Why? |
| Formative Feedback | 1 | 2018 | 56 | 0.05 | Why? |
| Primary Cell Culture | 1 | 2020 | 501 | 0.05 | Why? |
| Serotyping | 1 | 2018 | 154 | 0.05 | Why? |
| Nasopharynx | 1 | 2018 | 10224 | 0.05 | Why? |
| Electronic Mail | 1 | 2018 | 102 | 0.04 | Why? |
| Coronavirus Infections | 8 | 2021 | 253789 | 0.04 | Why? |
| Mutagenesis | 1 | 2019 | 394 | 0.04 | Why? |
| Palivizumab | 1 | 2017 | 32 | 0.04 | Why? |
| Multilocus Sequence Typing | 1 | 2018 | 264 | 0.04 | Why? |
| Random Allocation | 1 | 2020 | 773 | 0.04 | Why? |
| Toll-Like Receptor 4 | 1 | 2020 | 390 | 0.04 | Why? |
| Animals | 7 | 2020 | 78931 | 0.04 | Why? |
| Bacterial Typing Techniques | 1 | 2018 | 273 | 0.04 | Why? |
| Antibiotic Prophylaxis | 1 | 2020 | 399 | 0.04 | Why? |
| Mice, Inbred BALB C | 2 | 2018 | 5814 | 0.04 | Why? |
| Coinfection | 1 | 2017 | 6820 | 0.04 | Why? |
| Interleukin-13 | 1 | 2018 | 204 | 0.04 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2020 | 782 | 0.04 | Why? |
| Coronaviridae Infections | 1 | 2019 | 442 | 0.04 | Why? |
| Acute Disease | 2 | 2018 | 6029 | 0.04 | Why? |
| Humans | 22 | 2021 | 930598 | 0.04 | Why? |
| Virus Cultivation | 1 | 2018 | 579 | 0.04 | Why? |
| Child | 6 | 2021 | 70012 | 0.03 | Why? |
| Child, Hospitalized | 1 | 2018 | 556 | 0.03 | Why? |
| RNA, Ribosomal, 16S | 1 | 2018 | 793 | 0.03 | Why? |
| Feces | 2 | 2018 | 4235 | 0.03 | Why? |
| Cell Line | 2 | 2020 | 12040 | 0.03 | Why? |
| DNA, Bacterial | 1 | 2018 | 835 | 0.03 | Why? |
| Nose | 1 | 2020 | 1093 | 0.03 | Why? |
| Recombination, Genetic | 1 | 2021 | 1265 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2021 | 2437 | 0.03 | Why? |
| Time Factors | 3 | 2021 | 31397 | 0.03 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.03 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.03 | Why? |
| Prevalence | 3 | 2021 | 25773 | 0.03 | Why? |
| Prospective Studies | 4 | 2021 | 43301 | 0.03 | Why? |
| T-Lymphocytes | 2 | 2020 | 6670 | 0.03 | Why? |
| Viral Nonstructural Proteins | 2 | 2021 | 4810 | 0.03 | Why? |
| United States | 4 | 2021 | 46150 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 13720 | 0.03 | Why? |
| Middle East | 1 | 2017 | 1418 | 0.03 | Why? |
| Female | 11 | 2021 | 380317 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2020 | 3776 | 0.03 | Why? |
| Coronaviridae | 1 | 2017 | 923 | 0.03 | Why? |
| Immune Evasion | 1 | 2021 | 2081 | 0.03 | Why? |
| Cell Line, Tumor | 1 | 2019 | 3608 | 0.03 | Why? |
| Structure-Activity Relationship | 1 | 2017 | 2219 | 0.03 | Why? |
| Travel-Related Illness | 1 | 2018 | 1357 | 0.03 | Why? |
| Male | 10 | 2021 | 367725 | 0.03 | Why? |
| Disease Models, Animal | 2 | 2020 | 10998 | 0.03 | Why? |
| Respiratory Syncytial Virus, Human | 1 | 2017 | 846 | 0.02 | Why? |
| Young Adult | 4 | 2021 | 93724 | 0.02 | Why? |
| Cross Reactions | 1 | 2021 | 4374 | 0.02 | Why? |
| Mutation | 2 | 2020 | 12376 | 0.02 | Why? |
| Virus Diseases | 1 | 2007 | 3779 | 0.02 | Why? |
| Mice, Inbred C57BL | 1 | 2020 | 5542 | 0.02 | Why? |
| Aged | 6 | 2021 | 215776 | 0.02 | Why? |
| Vaccines, Synthetic | 1 | 2021 | 3231 | 0.02 | Why? |
| Adult | 7 | 2021 | 244371 | 0.02 | Why? |
| Lymphocyte Activation | 1 | 2018 | 2742 | 0.02 | Why? |
| Macaca mulatta | 1 | 2018 | 3716 | 0.02 | Why? |
| Microbiota | 1 | 2018 | 1240 | 0.02 | Why? |
| Real-Time Polymerase Chain Reaction | 2 | 2017 | 11367 | 0.02 | Why? |
| Middle Aged | 6 | 2021 | 270681 | 0.02 | Why? |
| Neutralization Tests | 1 | 2020 | 6698 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Antibody Formation | 1 | 2020 | 4038 | 0.02 | Why? |
| Protein Conformation | 1 | 2017 | 4386 | 0.02 | Why? |
| Immunogenicity, Vaccine | 1 | 2021 | 4624 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2017 | 5440 | 0.02 | Why? |
| Pandemics | 4 | 2021 | 389249 | 0.02 | Why? |
| Models, Molecular | 1 | 2020 | 7616 | 0.02 | Why? |
| Double-Blind Method | 1 | 2017 | 5988 | 0.02 | Why? |
| Risk | 1 | 2018 | 5288 | 0.02 | Why? |
| Immunization, Passive | 1 | 2021 | 10067 | 0.02 | Why? |
| Disease Susceptibility | 1 | 2017 | 4002 | 0.02 | Why? |
| Clinical Competence | 1 | 2018 | 3263 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Vero Cells | 1 | 2019 | 14117 | 0.02 | Why? |
| Pediatrics | 1 | 2018 | 2969 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2017 | 4849 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2015 | 3444 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.01 | Why? |
| RNA, Viral | 2 | 2020 | 32276 | 0.01 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.01 | Why? |
| Molecular Diagnostic Techniques | 1 | 2018 | 4239 | 0.01 | Why? |
| Logistic Models | 1 | 2017 | 9089 | 0.01 | Why? |
| Polymerase Chain Reaction | 1 | 2017 | 6740 | 0.01 | Why? |
| Betacoronavirus | 3 | 2020 | 204454 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2021 | 10649 | 0.01 | Why? |
| Lung | 2 | 2020 | 31049 | 0.01 | Why? |
| Signal Transduction | 1 | 2018 | 7207 | 0.01 | Why? |
| Contact Tracing | 1 | 2021 | 8448 | 0.01 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2021 | 11041 | 0.01 | Why? |
| Receptors, Virus | 1 | 2017 | 5659 | 0.01 | Why? |
| Immunity, Innate | 1 | 2018 | 6570 | 0.01 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.01 | Why? |
| Length of Stay | 1 | 2017 | 11042 | 0.01 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.01 | Why? |
| Risk Factors | 2 | 2018 | 71621 | 0.01 | Why? |
| Viral Load | 1 | 2018 | 15850 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.01 | Why? |
| Treatment Outcome | 1 | 2021 | 51732 | 0.01 | Why? |
| Age Factors | 1 | 2015 | 21039 | 0.01 | Why? |
| Cohort Studies | 1 | 2018 | 36005 | 0.01 | Why? |
| Disease Transmission, Infectious | 1 | 2017 | 9044 | 0.01 | Why? |
| Immunoglobulin G | 1 | 2017 | 21571 | 0.01 | Why? |
| Aged, 80 and over | 1 | 2017 | 88759 | 0.01 | Why? |
Chappell's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(166)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(352)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_